Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ATP6V1B1 | P15313 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341045 | 0.90 | MEN1 (0.55) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6582988 | 0.89 | MEN1 (0.54) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL14341046 | 0.86 | MEN1 (0.51) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL220979 | 0.86 | KMT2A (0.51) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6582463 | 0.85 | MEN1 (0.49) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6582589 | 0.85 | MEN1 (0.49) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6581825 | 0.85 | MEN1 (0.49) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6790410 | 0.84 | MEN1 (0.48) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6585948 | 0.83 | MEN1 (0.48) | MEN1KMT2AGLACYP2C9ATP6V1B1 | |
| SCHEMBL6582982 | 0.83 | EZH2 (0.56) | MEN1KMT2AGLAATP6V1B1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | claimed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | claimed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | claimed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | disclosed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | disclosed |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | IDO1, IDO2, INMT | MEN1 942/4885KMT2A 2229/4885GLA 3668/4885 |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | MEN1 2708/4885KMT2A 3757/4885GLA 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.